By: IPP Bureau
Last updated : February 12, 2026 8:58 am
Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health security
To bolster Mexico's health sovereignty, Moderna has entered into a five-year strategic agreement with the Mexican Government, BIRMEX, and Laboratorios Liomont. This partnership focuses on building local mRNA manufacturing resilience by supplying Moderna’s respiratory vaccine portfolio and facilitating a technology transfer to Liomont.
Under the deal, Liomont will utilize its advanced facilities to produce Moderna’s COVID-19 vaccine (mRNA-1273), ensuring a dependable, domestic supply of essential respiratory vaccines for the country.
In alignment with "Plan Mexico," a Mexican government initiative to increase investment and build local production capacity, Moderna and the Mexican Government will also collaborate on local clinical research and development programs based on Mexico's health priorities and work to strengthen its pandemic preparedness framework.
"We are proud to support Mexico in its mission to strengthen national health security," said Stéphane Bancel, Chief Executive Officer of Moderna. "Through this agreement, we will be able to provide the Mexican people with access to our respiratory vaccines and critical pandemic response capacity. This collaboration also reflects the growing demand for these vaccines in Mexico, and we are excited about the opportunity to support public health needs while driving sales growth through geographic diversification."
This agreement follows the recent Federal Commission for the Protection against Sanitary Risk (COFEPRIS) approval of Moderna's 2025-2026 COVID-19 vaccine for individuals aged 6 months and older, as well as the purchase adjudication with the Government of Mexico for the supply of up to 10 million doses of Moderna's 2025-2026 COVID-19 vaccine to Logística y Transporte para la Industria de la Salud, S.A.P.I. de C.V. (Medistik).